PharmaFocus Today – Page 25 – media

Signed a licensing agreement with Glenmark Specialty for the Ruikang trastuzumab project, with revenue potentially exceeding US$1.1 billion.

Hengrui Medicine recently announced the signing of a licensing agreement with Glenmark Specialty SA for the Ruikang Trastuzumab project. The agreement provides for a paid license to Glenmark Specialty SA for the company’s innovative Class 1 drug, Ruikang Trastuzumab (SHR-A1811), for which the company holds independent intellectual property rights. Ruikang Trastuzumab is an antibody-drug conjugate (ADC) independently developed by Hengrui that targets HER2. It binds to and is internalized by HER2-expressing tumor cells. Within the tumor cell lysosome, trastuzumab releases a toxin through proteolytic cleavage, inducing cell cycle arrest and ultimately apoptosis. The released toxin is highly permeable, exerting a bystander effect and further enhancing anti-tumor efficacy. The company’s Ruikang Trastuzumab was approved for marketing in China in May 2025. It is indicated for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) activating mutations and have previously received ...
- Source: drugdu
- 135
- October 9, 2025
The application for marketing authorization of trivalent influenza virus split vaccine has been accepted

People’s Finance News reported on September 24 that Kangtai Biological(300601) announced on September 24 that the influenza vaccine developed by the companyThe application for marketing authorization of the viral split vaccine recently received an acceptance notice issued by the National Medical Products Administration. The influenza virus split vaccine 　　whose marketing authorization application was accepted this time is a trivalent influenza vaccine. Together with the quadrivalent influenza virus split vaccine that the company has applied for production registration, the quadrivalent influenza virus split vaccine (for people aged 6-35 months) that has been approved for clinical trials, the quadrivalent influenza virus split vaccine (MDCK cells) and the trivalent influenza virus split vaccine (MDCK cells), they constitute an influenza vaccine series covering all age groups. https://finance.eastmoney.com/a/202509243522587919.html
- Source: drugdu
- 88
- October 8, 2025
Walvax Biopharma’s vaccine receives Jordanian Drug Registration Certificate, marking a key step forward in its Middle East market expansion.

　　Shanghai Securities News China SecuritiesNet News (Reporter Sun Zhong) Walvax BioAn announcement on the 29th stated that the 13-valent pneumococcal polysaccharide conjugate vaccine produced by its subsidiary Yuxi Walvax recently received a “Drug Registration Certificate” issued by the Jordan Food and Drug Administration. 　　The Yuxi Walvax 13-valent pneumococcal polysaccharide conjugate vaccine is mainly suitable for vaccination of infants and children aged 6 weeks to 5 years (before the age of 6 years). It is used to prevent infectious diseases caused by the 13 serotypes of pneumococcus contained in this vaccine (type 1, type 3, type 4, type 5, type 6A, type 6B, type 7F, type 9V, type 14, type 18C, type 19A, type 19F and type 23F). The vaccine was approved for sale in China in 2020. 　　Currently, pneumococcal infection remains one of the leading causes of death in children under five worldwide. In Jordan, this infection also poses a ...
- Source: drugdu
- 102
- October 8, 2025
Zhifei Bio’s independent product, influenza virus split vaccine, has obtained a drug registration certificate

　　Zhifei BioinfluenzaThe vaccine matrix has added another blockbuster product. The company announced on the evening of September 29 that the influenza virus split vaccine (referred to as “trivalent influenza vaccine”; registration category: preventive biological product) recently developed by its wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.) Obtain the “Drug Registration Certificate” issued by the State Food and Drug Administration. 　　Influenza is an acute respiratory infectious disease caused by the influenza virus that can cause widespread epidemics. It is highly contagious and can cause complications such as pneumonia, bronchitis, and myocarditis. It can aggravate underlying conditions in high-risk groups such as the elderly and the frail, increasing the disease burden and endangering human health. Flu vaccination is the most economical and effective measure to prevent influenza illness and influenza outbreaks. The trivalent influenza vaccine developed by Zhifei Longcoma is suitable for people aged three years and older to prevent infectious ...
- Source: drugdu
- 108
- October 8, 2025
Antihypertensive and lipid-lowering drugs show efficacy against steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one third of the adult population. This disorder is characterized by the accumulation of fat in liver cells, which has severe liver consequences and is also associated with a high mortality rate from cardiovascular disease. Now, a University of Barcelona study published in the journal Pharmacological Research shows that pemafibrate and telmisartan, two drugs already approved for other conditions, effectively reduce fat accumulation in laboratory animal models of metabolic liver disease. Furthermore, the study suggests that this combination of drugs may help to reduce both liver involvement and associated cardiovascular complications. These results open the door to the development of safer and more effective treatments for this disease, for which current therapeutic options are very limited. The study has been carried out by a team led by Marta Alegret, professor at the ...
- Source: drugdu
- 159
- October 7, 2025
Large-scale analysis offers insights into sporadic nature of chikungunya virus outbreaks

While the virus is common in tropical and subtropical regions, including Asia, Africa and South America, public health officials have been tracking reported infections in Europe and, in September, a confirmed case in Long Island, New York. Outbreaks of chikungunya have prompted the Centers for Disease Control to issue health notices to travelers bound for Bangladesh; Cuba; Guangdong Province, China; Kenya; Madagascar; Somalia; and Sri Lanka. In Guangdong Province, an”unprecedented”outbreak recently prompted government officials in China to mandate quarantines for anyone suspected of being infected by the virus, spraying individuals with mosquito repellent and spraying impacted buildings and other areas with insecticide. In a new study, published in Science Advances, researchers at the University of Notre Dame analyzed more than 80 outbreaks of chikungunya virus to improve prediction of future outbreaks and inform vaccine trial development. “Chikungunya outbreaks are unpredictable in both size and severity,”said Alex ...
- Source: drugdu
- 138
- October 7, 2025
UK health agency urges people to get vaccinated against respiratory viruses before winter

The UK Health and Safety Agency (UKHSA) announced on the 26th that as winter approaches, influenzaThe number of cases of COVID-19, COVID-19 and respiratory syncytial virus (RSV) is on the rise, and the public is urged to make appointments for relevant vaccines as soon as possible. 　　The latest UK national influenza and COVID-19 surveillance report shows that related cases have been steadily increasing over the past few weeks. The COVID-19 positive rate has risen from 7.6% to 8.4% in one week, and the number of COVID-19 hospitalizations per 100,000 people has also increased from 2 to 2.73. UKHSA emphasizes that before the peak season of respiratory diseases arrives, people should receive timely medical treatment from the UK National Health Service.The free vaccinations are provided by the National Health Service (NHS). Pregnant women and millions of children are already eligible for the vaccine, and most eligible groups can make an appointment from October 1. This ...
- Source: https://finance.eastmoney.com/a/202509263525102518.html
- 140
- October 6, 2025
Beike Bio responded to the inquiry letter regarding its semi-annual report and detailed the reasons for the decline in herpes zoster vaccine sales.

Beike BioA response was made to the regulatory inquiry letter regarding information disclosure in the 2025 semi-annual report, mentioning the reasons for the decline in sales of shingles vaccine. 　　In the first half of 2025, the company’s operating income was 285 million yuan, a year-on-year decrease of 53.93%; the net profit was -73.5734 million yuan, turning from profit to loss year-on-year. The company disclosed that the decline in performance was mainly due to the decline in sales of shingles vaccine. 　　The announcement showed that during the reporting period, the company’s sales volume of shingles vaccine was -17,300 doses, with sales revenue of -65.2266 million yuan. 　　Beike Bio believes that factors such as product price structure, vaccination demand, low disease awareness, insufficient consumption willingness of the applicable group, and vaccine hesitation affect the product revenue. 　　The company stated in its response that during the reporting period, sales of herpes zoster vaccines decreased ...
- Source: https://finance.eastmoney.com/a/202509303526642756.html
- 144
- October 6, 2025
Dongcheng Pharmaceutical’s subsidiary’s new prostate cancer drug approved for clinical trials

Dongcheng Pharmaceutical recently announced that its controlling subsidiary, Lannacheng, has received approval from the National Medical Products Administration (NMPA) for the clinical trial of 225Ac-LNC1011 injection, authorizing it to conduct clinical trials for prostate cancer. This drug, an alpha-particle radioactive in vivo therapeutic targeting prostate-specific membrane antigen (PSMA), is intended for the treatment of patients with advanced prostate cancer who are PSMA-positive. Currently, no similar product is marketed outside of China , and no sales data is available. The project has invested approximately 14.53 million yuan in R&D. In completed animal and human trials, 225Ac-LNC1011 injection has demonstrated therapeutic potential for prostate cancer. However, the drug development cycle, clinical trial approval, and production are long and involve many steps. Investors need to be aware of the risk of drug development failure.
- Source: https://www.stcn.com/article/detail/3353547.html
- 143
- October 5, 2025
Rectal bleeding increases the odds of colorectal cancer diagnosis by 8.5 times

Adults under 50 undergoing colonoscopy were found to have a dramatically higher risk of having colorectal cancer when the procedure was done for rectal bleeding. Researchers found that rectal bleeding increased the odds of a colorectal cancer diagnosis by 8.5 times, underscoring the need to take the symptom seriously even in the absence of a family history in a population who may not otherwise meet screening age criteria. The research will be presented at the American College of Surgeons (ACS) Clinical Congress 2025 in Chicago, October 4-7. The retrospective study analyzed 443 patients under 50 who underwent a colonoscopy at the University of Louisville Health System between 2021 and 2023. Of them, 195 (44%) were diagnosed with early-onset colorectal cancer, while 248 (56%) had normal results. “Many of the early-onset colorectal cancers that I see have no family history. This research lends support to the question of ...
- Source: drugdu
- 136
- October 5, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.